EASL 2017 Gregory Dore at the International Liver Congress 2017. Photo by Liz Highleyman, hivandhepatitis.comLiver cancerDirect-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies. Xavier Forns at the International Liver Congress 2017. Photo by Liz Highleyman, hivandhepatitis.comHepatitis C treatmentNew AbbVie hepatitis C combination cures 99% of people with cirrhosis. Richard Moreau at the International Liver Congress 2017. Photo by Liz Highleyman, hivandhepatitis.comAntibiotic prophylaxisAntibiotic prophylaxis reduces the risk of short-term death in people with decompensated cirrhosis. infohep news Treatment in cirrhosis Albumin reduces complications and improves survival in people with decompensated cirrhosis Liz Highleyman / 08 May 2017 Long-term administration of human albumin was associated with fewer serious complications, less hospitalisation, better quality of life and longer survival for people with decompensated liver cirrhosis, according to a report at the International ... Hepatitis B Besifovir and tenofovir exalidex look promising as new hepatitis B drug Liz Highleyman / 04 May 2017 Two investigational nucleotide analogue antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the International Liver Congress last week in Amsterdam. ... Resistance Triple combination cures most hepatitis C patients with prior DAA treatment failure Liz Highleyman / 02 May 2017 Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a three-drug combination ... Treatment guidelines EASL releases updated hepatitis B guidelines at International Liver Congress Liz Highleyman / 26 April 2017 The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection – the first update since 2012 – during a ... Hepatitis B Switching to TAF for hepatitis B improves kidney function and bone loss Liz Highleyman / 26 April 2017 People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at ... Access to medicines & diagnostics Generic hepatitis C drugs continue to produce high cure rates Keith Alcorn / 24 April 2017 Treatment with generic versions of direct-acting antiviral drugs continues to produce similar cure rates to those reported in clinical trials, Dr James Freeman reported last week at the International Liver ... Treatment in liver transplanted HCV treatment allows one in four people to come off the transplant waiting list Keith Alcorn / 24 April 2017 Around one in four people with hepatitis C and decompensated cirrhosis came off the transplant waiting list in Europe after direct-acting antiviral treatment, and very few had any subsequent liver-related ... Hepatocellular carcinoma (HCC) Nivolumab increases survival for people with advanced liver cancer Liz Highleyman / 22 April 2017 The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well tolerated as a treatment for advanced liver cancer that did not respond to standard treatment, researchers reported on ... Treatment outcomes Children with hepatitis C respond well to sofosbuvir/ledipasvir Liz Highleyman / 22 April 2017 Almost all children with hepatitis C, aged 6 to 11 years, who were treated with a half-strength tablet of sofosbuvir/ledipasvir were cured, which is important as some of them had advanced liver ... Genotype 3 AbbVie combination cures 97% of genotype 3 hepatitis C Keith Alcorn / 21 April 2017 AbbVie's pangenotypic direct-acting antiviral combination of two drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV), the hardest genotype to treat, according to results of the ENDURANCE-3 ... View more > Editors' picks from other sources Treatment for previous non-responders & relapsers Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C Merck press release / 24 April 2017 Treatment and HCV genotype Shortened duration triple therapy fails in genotype 3 HCV Healio Hepatology / 24 April 2017 Epidemiology One-third of UK adolescents with HCV developed serious liver disease Healio Hepatology / 22 April 2017 International policy WHO's Global Hepatitis Report sets baseline to eliminate viral hepatitis by 2030 World Hepatitis Alliance / 21 April 2017 Epidemiology New hepatitis data highlight need for urgent global response World Health Organization / 21 April 2017 Access to medicines & diagnostics The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir Medicines Patent Pool / 21 April 2017 National policy Global HCV elimination requires changes in prescribing, access, policy Healio Hepatology / 21 April 2017 Fibrosis NASH: It's Fibrosis, Not Fat, that Matters MedPage Today Gastroenterology / 21 April 2017 Disease course and symptoms Fecal microbiota transplants improve cognitive impairment caused by severe liver disease EASL / 21 April 2017 Hepatocellular carcinoma (HCC) Nivolumab produces durable responses & long-term survival in severe liver cancer patients Eurekalert Inf Dis / 21 April 2017 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive